Trials / Completed
CompletedNCT02945449
Safety of Wharton Jelly in Erectile Dysfunction
Phase Ib: Evaluation of the Safety and as a Secondary End Point the Efficacy for Two Doses of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Sophia Al-Adwan · Academic / Other
- Sex
- Male
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Safety of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.
Detailed description
This study will be conducted at the Cell Therapy Center (CTC), Jordan, in which nine male patients ranging from 25-70 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests. The patients are followed by clinical assessment, laboratory investigations as well as Doppler ultrasound.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Wharton Jelly Mesenchymal stem cells | Intracavernous injection of Wharton Jelly Mesenchymal stem cells. |
Timeline
- Start date
- 2017-01-04
- Primary completion
- 2018-10-15
- Completion
- 2018-11-01
- First posted
- 2016-10-26
- Last updated
- 2018-11-15
Locations
1 site across 1 country: Jordan
Source: ClinicalTrials.gov record NCT02945449. Inclusion in this directory is not an endorsement.